Atrin Pharmaceuticals
Atrin Pharmaceuticals is a private biopharmaceutical company pioneering the discovery & development of proprietary molecules targeting DNA Damage and Response (DDR) pathways to treat a broad spectrum of cancers associated with synthetic lethality and the deregulated DNA Damage Response.
The concept of synthetic lethality is that cells can tolerate the loss of function of a single gene/protein as a stand alone but not in combination with the loss of function of another gene/protein. When one pathway is functionally lost in cancer, it increased the reliance on another gene/protein to maintain viability. Atrin is targeting the DDR pathway to develop new medicines to treat patients with a broad spectrum of cancers through selective synthetic lethal interactions.
Atrin’s scientific founders were the first to discover the key role of the Ataxia Telangiectasia and Rad3-related (ATR) pathway in treating cancers.
The emerging role of DDR treatments in cancer is expected to represent a cornerstone in novel targeted monotherapy and combination anticancer therapies. Atrin’s lead ATR molecules are projected to become best-in-class DDR inhibitors.
Atrin’s lead product is ATRN-119, a novel, potentially best-in-class small molecule ATR inhibitor. Atrin plans to initiate a first-in-human trial for ATRN-119 in early 2022.
